Introduction {#s1}
============

Muscular dystrophies (MD), an inherited group of degenerative skeletal muscle disorders, are characterized by progressive/congenital weakness and breakdown of skeletal muscles encompassing great clinical and genetic heterogeneity, and even death because of cardiomyopathy and respiratory failure ([@B26]; [@B11]; [@B4]). Currently, MD are clinically classified to six categories with various degree of severity, including Duchenne MD (DMD) and Becker MD (BMD), limb-girdle MD (LGMD), distal MD, congenital MD (CMD), facio-scapulo-humeral MD, and myotonic MD ([@B11]). DMD/BMD that are caused by mutations in X chromosome-linked *dystrophin* (*DMD*) are the most common forms in childhood with an estimated incidence of 8.3 or 7.3 per 100,000 male ([@B46]; [@B4]). DMD, a severe phenotype clinically, is characterized by a progressive loss of muscle function with onset at age 2 to 5 years, lost ambulation before age 13 years and death at approximately 20 years of age, while BMD shows a mild form with patients being loss of ambulantion after 16 years of age ([@B26]; [@B46]; [@B48]). Other forms of MD are mostly autosomal recessive with rare prevalence in childhood but vary in region ([@B26]; [@B46]; [@B50]; [@B24]; [@B45]).

*DMD* is the largest gene in human, spanning 2.4 Mb of genomic region on Xp21, and containing 79 exons and 78 lengthy introns, which produces a 14.6 kb mRNA transcript ([@B2]). To date, many mutations in *DMD* have been described, approximately 70% of which are large deletions/duplications (≥1 exon), while the remaining 25% to 30% are caused by small mutations (\<1 exon), encompassing point mutations or small deletions/insertions ([@B48]). The differences of clinical manifestations between BMD and DMD result from different mutation types in *DMD* gene. Patients will suffer from DMD when the mutation leads to a frameshift (out of frame) or generates a premature stop codon; non-functional dystrophin protein is produced. On the contrary, patients will present the phenotype of BMD when the mutation maintains in reading frame (in-frame mutation); a partially functional dystrophin protein is produced ([@B28]).

Recently, several promising mutation-specific molecular therapies have been developed, including exon skipping to restore the reading frame and increase expression of the compensatory dystrophin, and read-through therapy of a nonsense codon to produce full-length dystrophin which is applicable to harbor nonsense mutations for patients with DMD. Therefore, it is essential to make an early and accurate diagnosis for the patients with suspected MD to provide information on eligibility of mutation-specific treatments as well as optimal care and family planning. Multiplex ligation-dependent probe amplification (MLPA), a simple and rapid screening tool, has been developed and used to test large deletions and duplications of all 79 exons in *DMD* gene in different populations ([@B14]; [@B16]; [@B39]). As the small mutations are easily missed by MLPA ([@B38]), next-generation sequencing (NGS) has been applied for MLPA-negative patients and indicated high efficiency and cost-effectiveness but varied prevalence and mutation types in different populations of locations ([@B31]; [@B44]; [@B37]).

In this study, 70 patients clinically suspected MD and their families from Shandong province of China were investigated; MLPA was firstly used to detect large deletions and duplications in *DMD* gene in probands; then, NGS was applied to find small mutations in the MLPA-negative patients. The mutation patterns and hot spot locations were analyzed in order to establish genotype-phenotype correlations, and a reference for the development of gene therapy.

Materials and Methods {#s2}
=====================

Patients and Samples {#s2_1}
--------------------

A total of 70 unrelated hospitalized children (67 boys and three girls, mean age 3.47 ± 2.97 years; see [**Table 1**](#T1){ref-type="table"} for details) with a clinically suspected diagnosis of MD and their healthy parents were enrolled in this study in Qilu Children's Hospital of Shandong University (QCHSU) from July 2015 to December 2017, including 36 clinically suspected DMD, six suspected BMD, and 28 UMD (uncertain MD) without typical clinical phenotype due to relatively young age.

###### 

The clinical and laboratory features of the 70 clinically suspected muscular dystrophy (MD) probands.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient\          Sex      Age (years)   Clinical manifestation                                                                                                    CK value\   EMG:\                     Clinical diagnosis   Genotypes
  ID                                                                                                                                                                 (U/L)       myopathic abnormalities                        
  ----------------- -------- ------------- ------------------------------------------------------------------------------------------------------------------------- ----------- ------------------------- -------------------- ---------------------------
  P2                Male     7.9           Difficulty walking, Gowers sign, proximal muscle weakness, calf muscle pseudohypertrophy                                  16,470      NA                        DMD                  *DMD*: DelEX2

  P3                Male     7.3           Difficulty walking, Gowers sign, difficulty climbing stairs, proximal muscle weakness                                     49,328      NA                        DMD                  *DMD*: DelEX3-13

  P4                Male     1.8           Gowers sign                                                                                                               26,963      NA                        DMD                  *DMD*: DelEX3-29

  P5                Female   2.4           Progressive muscle weakness                                                                                               5,521       \+                        DMD-like             *DMD*: DelEX8-12

  P6                Male     8.0           Difficulty walking, muscular hypotonia, waddling gait, falls, difficulty climbing stairs, Gowers sign                     13,684      NA                        DMD                  *DMD*: DelEX8-23

  P7                Male     2.7           Muscular hypotonia, calf muscle pseudohypertrophy                                                                         46,191      \+                        DMD                  *DMD*: DelEX10-44

  P8                Male     2.9           Progressive muscle weakness                                                                                               6,093       \+                        DMD                  *DMD*: DelEX13

  P13               Male     7.3           Difficulty walking, waddling gait, falls, difficulty climbing stairs, Gowers sign                                         22,001      \+                        DMD                  *DMD*: DelEX45

  P18               Male     7.6           Progressive muscle weakness, falls, waddling gait                                                                         16,427      NA                        DMD                  *DMD*: DelEX45-54

  P19               Male     1.8           Progressive muscle weakness                                                                                               16,530      \+                        DMD                  *DMD*: DelEX45-54

  P23               Male     6.2           Difficulty walking, difficulty climbing stairs, calf muscle pseudohypertrophy, progressive muscle weakness                12,270      \+                        DMD                  *DMD*: DelEX46-55

  P25               Male     7.0           Waddling gait, difficulty climbing stairs, Gowers sign                                                                    12,537      NA                        DMD                  *DMD*: DelEX48-50

  P27               Male     9.0           Difficulty walking, difficulty climbing stairs, Gowers sign, falls, waddling gait                                         17,713      NA                        DMD                  *DMD*: DelEX49-50

  P30               Female   8.0           Progressive muscle weakness, calf muscle hypertrophy                                                                      13,323      NA                        DMD                  *DMD*: DelEX50

  P31               Male     1.1           Difficulty walking                                                                                                        10,491      NA                        DMD                  *DMD*: DelEX50-52

  P32               Male     3.0           Progressive muscle weakness, Gowers sign                                                                                  25,758      NA                        DMD                  *DMD*: DelEX50-52

  P35               Male     9.0           Progressive muscle weakness, difficulty climbing stairs, Gowers sign                                                      17,771      \+                        DMD                  *DMD*: DelEX51

  P36               Male     7.0           Calf muscle pseudohypertrophy, Gowers sign                                                                                14,659      NA                        DMD                  *DMD*: DelEX51

  P37               Male     3.2           Calf muscle pseudohypertrophy                                                                                             25,596      NA                        DMD                  *DMD*: DelEX51-55

  P38               Male     7.5           Difficulty walking, difficulty climbing stairs, Gowers sign, progressive muscle weakness, Calf muscle pseudohypertrophy   20,051      NA                        DMD                  *DMD*: DelEX51-55

  P41               Male     4.0           Progressive muscle weakness                                                                                               9,765       \+                        DMD                  *DMD*: DelEX53-55

  P43               Male     1.8           Gowers sign                                                                                                               10,001      \+                        DMD                  *DMD*: DelEX55-77

  P44               Male     2.0           Delayed gross motor development                                                                                           7,307       \+                        DMD                  *DMD*: DelEX56-79

  P46               Male     6.7           Progressive muscle weakness, waddling gait, Calf muscle pseudohypertrophy, Gowers sign                                    10,578      \+                        DMD                  *DMD*: DelEX62

  P48               Male     7.4           Muscle weakness, motor delay                                                                                              16,320      NA                        DMD                  *DMD*: DupEX3-7

  P49               Male     5.6           Motor delay, muscle weakness                                                                                              19,726      \+                        DMD                  *DMD*: DupEX5-7

  P50               Male     2.7           Progressive muscle weakness, difficulty climbing stairs, Gowers sign, calf muscle pseudohypertrophy                       31,680      NA                        DMD                  *DMD*: DupEX19-21

  P51               Male     7.0           Difficulty walking, Gowers sign, calf muscle pseudohypertrophy                                                            5,243       \+                        DMD                  *DMD*: DupEX45-54

  P52               Male     2.1           Difficulty walking, calf muscle pseudohypertrophy                                                                         23,479      \+                        DMD                  *DMD*: c.2436C \> T

  P53               Male     6.4           Calf muscle hypertrophy, progressive muscle weakness                                                                      15,401      NA                        DMD                  *DMD*: c.7264dupG

  P54               Male     4.0           Progressive muscle weakness, calf muscle pseudohypertrophy                                                                2,6917      \+                        DMD                  *DMD*: c.1231A \> T

  P57               Male     3.1           Calf muscle pseudohypertrophy                                                                                             8,372       \+                        DMD                  *DMD*: c.5167G \> T

  P58               Male     2.3           Delayed gross motor development                                                                                           35,951      \+                        DMD                  *DMD*: 10187delC

  P61               Male     7.0           Difficulty walking, Gowers sign, calf muscle pseudohypertrophy                                                            15,795      NA                        DMD                  *DMD*: c.2571delC

  P68               Male     5.4           Gowers sign                                                                                                               20,611      NA                        DMD                  Unknown

  P69               Male     1.7           Calf muscle pseudohypertrophy                                                                                             4,938       NA                        DMD                  Unknown

  P14               Male     3.7           Calf muscle pseudohypertrophy                                                                                             3,087       --                        BMD                  *DMD*: DelEX45-47

  P16               Male     9.9           Difficulty climbing stairs, calf muscle pseudohypertrophy                                                                 5,641       NA                        BMD                  *DMD*: DelEX45-47

  P17               Male     5.3           Calf muscle pseudohypertrophy                                                                                             12,744      \+                        BMD                  *DMD*: DelEX45-48

  P56               Male     3.8           Calf muscle pseudohypertrophy                                                                                             5,149       NA                        BMD                  *DMD*: c.1812 + 1C \> T

  P65               Male     5.6           Calf muscle pseudohypertrophy                                                                                             13,783      \+                        BMD                  Unknown

  P70               Male     11.0          No                                                                                                                        2,095       NA                        BMD                  Unknown

  P1                Male     0.2           No                                                                                                                        14,982      \+                        UMD                  *DMD*: DelEX1-79

  P9                Male     1.7           No                                                                                                                        4,315       NA                        UMD                  *DMD*: DelEX26-34

  P10               Male     0.4           No                                                                                                                        20,053      NA                        UMD                  *DMD*: DelEX44

  P11               Male     0.8           No                                                                                                                        5,325       NA                        UMD                  *DMD*: DelEX44-55

  P12\`             Male     0.6           No                                                                                                                        35,340      NA                        UMD                  *DMD*: DelEX45

  P15               Male     1.0           No                                                                                                                        4,007       NA                        UMD                  *DMD*: DelEX45-47

  P20               Male     0.6           No                                                                                                                        16,936      \+                        UMD                  *DMD*: DelEX45-54

  P21               Male     0.1           No                                                                                                                        53,053      \+                        UMD                  *DMD*: DelEX46-48

  P22               Male     0.9           Calf muscle pseudohypertrophy                                                                                             7,692       \+                        UMD                  *DMD*: DelEX46-52

  P24               Male     0.1           No                                                                                                                        10,935      \+                        UMD                  *DMD*: DelEX46-55

  P26               Male     1.7           No                                                                                                                        16,753      \+                        UMD                  *DMD*: DelEX49-50

  P28               Male     0.7           No                                                                                                                        5,927       \+                        UMD                  *DMD*: DelEX49-52

  P29               Male     0.1           No                                                                                                                        6,360       NA                        UMD                  *DMD*: DelEX49-52

  P33               Male     1.2           No                                                                                                                        16,428      \+                        UMD                  *DMD*: DelEX51

  P34               Male     0.7           No                                                                                                                        17,001      \+                        UMD                  *DMD*: DelEX51

  P39               Male     1.0           No                                                                                                                        8,178       \+                        UMD                  *DMD*: DelEX52

  P40               Male     0.6           No                                                                                                                        9,606       \+                        UMD                  *DMD*: DelEX53

  P42               Male     0.8           No                                                                                                                        4,561       \+                        UMD                  *DMD*: DelEX55

  P45               Male     0.7           No                                                                                                                        10,444      \+                        UMD                  *DMD*: DelEX61

  P47               Male     0.1           No                                                                                                                        21,064      \+                        UMD                  *DMD*: DelEX69-71

  P55               Male     0.9           Calf muscle pseudohypertrophy                                                                                             3,676       \+                        UMD                  *DMD*: c.580C \> T

  P59               Male     1.2           No                                                                                                                        10,456      NA                        UMD                  *DMD*: c.7660 + 1C \> G

  P60               Male     1.0           No                                                                                                                        20,926      NA                        UMD                  *DMD*: c.7792C \> T

  P62               Male     1.0           Calf muscle pseudohypertrophy                                                                                             21,234      NA                        UMD                  *DMD*: c.6283C \> T

  P63               Female   0.6           Muscle weakness, muscular hypotonia, motor delay, dysphagia, weak cry                                                     2,594       \+                        UMD                  *LAMA2*: c.2049_2050delAG

  *LAMA2*:DelEX 4                                                                                                                                                                                                               

  P64               Male     0.4           Muscle weakness, muscular hypotonia, motor delay, dysphagia, weak cry                                                     2,391       \+                        UMD                  *LAMA2*:c.1672C \> T/

  *LAMA2*:DelEX 4                                                                                                                                                                                                               

  P66               Male     1.7           No                                                                                                                        2,913       NA                        UMD                  Unknown

  P67               Male     3.0           No                                                                                                                        4,093       NA                        UMD                  Unknown
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All the variants in DMD gene and LAMA2 gene shown in [**Table 1**](#T1){ref-type="table"} **and** [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"} are described using the NM_004006.2 transcript and the NM_000426.3 transcript reference sequence, respectively.

Del, deletion; Dup, duplication; EX, Exon; DMD, Duchenne's Muscular Dystrophy; BMD, Becker Muscular Dystrophy; UMD, unclear phenotype because of young age.

NA, not available; "+": Present; "-": Absent.

All participants were from Han Chinese population in Shandong Province, north of China. All probands were examined and diagnosed by experienced neuromuscular specialists at Neurology Department of QCHSU. Clinical diagnosis was based on clinical features including: 1) significantly increased serum creatine kinase (CK) level; 2) myopathic abnormalities, but normal peripheral nerve conduction velocity on EMG; 3) a positive family history with MD; 4) muscular weakness; 5) difficulty in walking; 6) Gowers sign; 7) calf muscle pseudohypertrophy; 8) difficulty climbing stairs; and 9) waddling gait and so on ([@B26]; [@B4]).

The inclusion criteria for the probands enrolling in this study were in accord with clinical features of (1) or (1) and (2) or (1) and (2) plus one or several other features described above.

We excluded patients had no clinical feature (1). The clinical diagnosis of DMD is based on: 1) progressive symmetric muscle weakness (proximal \> distal) often with calf hypertrophy, 2) symptoms present before age 5 years, and 3) lost ambulation before age 13 years. The clinical diagnosis of BMD is based on: 1) progressive symmetric muscle weakness (proximal \> distal) often with calf hypertrophy, 2) activity-induced cramping (present in some individuals), 3) flexion contractures of the elbows (if present, late in the course), 4) lost ambulation after age 16 years, and 5) preservation of neck flexor muscle strength (differentiates BMD from DMD) ([@B8]). Some patients, who could not be classified in this way, were recognized as DMD when an onset of weakness occurred by the age of 5, or considered as BMD when they had very mild or nearly normal motor dysfunction after 5 years old ([@B25]).

In addition, we used "UMD" to describe the uncertain MD types of the patients who cannot be diagnosed due to very young age, only manifesting persistent hyperCKemia and typical myopathy manifestation on EMG but normal peripheral nerve conduction velocity.

Blood samples obtained from the subjects were collected in EDTA vacutainer, and genomic DNA was extracted by using QIAamp DNA Blood Mini Kit (Qiagen, Shanghai, China) following the manufacturer's instructions. MLPA was used as the first-line molecular detection, and NGS was applied to detect small mutations in MLPA-negative samples (The work flow chart of the study was shown in [**Figure 1**](#f1){ref-type="fig"}).

![Flow chart of this study design. A total of 70 subjects with suspected MD underwent MLPA, and 51 were positive including 41 out of frame mutations and 10 in-frame mutations, while in the rest of the 19 subjects with negative MLPA and two female with positive MLPA, NGS was performed, with 11 positive in *DMD* and 2 positive in *LAMA2*.](fphar-10-00814-g001){#f1}

MLPA Assay {#s2_2}
----------

The MLPA reaction was carried out to screen all exons of *DMD* using SALSA MLPA probe sets P034 and P035 (MRC-Holland, Amsterdam, the Netherlands) according to the manufacturer's instructions. Amplified products were separated using a 3500 XL Genetic Analyzer (ABI, Carlsbad, CA, USA), and the data were analyzed by Coffalyser Software (MRC-Holland, Amsterdam, the Netherlands).

Next-Generation Sequencing {#s2_3}
--------------------------

Totally, 1,500 ng genomic DNA was fragmented to an average size of 300 bp; then, the fragmented genomic DNA was used to prepare sequencing libraries and 8 bp barcoded sequencing adapters were ligated to the DNA fragments before final hybridization with SureSelect captured Exome probes (Agilent, Santa Clara, CA, USA). The quality and quantity of the libraries were assessed by both Advanced Analytical Technologies Inc. (AATI) Fragment Analyzer (Ankeny, Des Moines, IA, USA) and qPCR. Purified sequencing libraries were pooled together and massively parallel-sequenced using Illumina HiSeq X Ten platform yielding an average of 1.5 Gb of total sequence per sample at an average sequencing depth of 100×. The data were then aligned to version GRCh37/hg19 of the human genome in NextGENe Software v2.3.4 (SoftGenetics, State College, PA, USA) that aligned sequence reads to the reference. NextGENe Software uses a preloaded index alignment algorithm that employs a suffix array that is represented by the Burrows-Wheeler Transform (BWT).

Both the general pipelines for NGS data analyses of diseases and data analysis strategies for the pathogenic genes of MD were conducted according to the recommendations from Jin et al. (2018). Variants were classified according to the 2015 ACMG guideline for the interpretation of sequence variants. All the mutations that can potentially cause the diseases were verified by Sanger sequencing on a 3130 Genetic Analyzer (ABI, Carlsbad, CA, USA).

Validation of Gene Mutations {#s2_4}
----------------------------

Quantitative PCR (qPCR) and Sanger sequencing were then utilized to validate the potentially pathogenic variants of exon deletions/duplications and small mutations in the patients with designed specific primers. The qPCR was amplified according to the manufacturer's recommendations on a real-time PCR system (LightCycler 480 II, Roche, Foster City, USA). Copy number variations were determined based on the ratio of copies of the deletion fragment to a reference gene (*GAPDH*) with the SYBR Premix Ex Taq II PCR reagent kit (TakaRa Bio, Dalian, China) according to the manufacturer's protocol. The PCR products were puriﬁed and sequenced using an ABI Prism 3700 automated sequencer (Applied Biosystems, Foster City, CA).

Statistical Analysis {#s2_5}
--------------------

SPSS 17.0 (IBM, Armonk, NY, United States) was used for statistical analyses. Two-sided Fisher's test was used to compare CK value between BMD and UMD. Correlations between phenotypes and factors (age of examination, mutation type, and CK values as mean ± SD) were analyzed using logistic regression. It was considered statistically significant when *P* value was less than 0.05, and the confidence interval was 95%.

Results {#s3}
=======

Clinical Findings {#s3_1}
-----------------

In total, 70 Chinese families with 70 clinically suspected MD patients were enrolled in the study, including 42 with a clinically suspected DMD/BMD (36 suspected DMD and 6 suspected BMD), and 28 (named as UMD, mean age 0.64 ± 0.34 years) lack of clinical phenotype due to relatively young age, with only persistent hyperCKemia and typical myopathy manifestation on EMG but normal peripheral nerve conduction velocity.

The average CK values for these patients clinically diagnosed with DMD and BMD were 17,528.33 ± 10,234.82 U/L and 6,017.71 ± 2,890.50 U/L, respectively, which indicated a significant difference between both categories (*P* \< 0.01) ([**Table 1**](#T1){ref-type="table"}).

Detection of Mutations in *DMD* by MLPA {#s3_2}
---------------------------------------

Large rearrangements in *DMD* were detected in the 70 probands using MLPA and validated by qPCR. A total of 51 (72.9%) deletions and duplications were found in 51 patients including two girls, 47 (75.8%) of which were deletions, and 4 were duplications (6.5%). Overall, 38 different rearrangements were identified. Among the 51 positive results, 41 showed out of frame mutations (37 large deletions, 4 large duplications) and 10 showed in-frame mutations (deletions). Of the 41 out of frame mutations, 25 were found in clinically diagnosed DMD patients, and 16 in very young UMD patients. Among the patients with 10 in-frame mutations, 5 BMD, 4 DMD, and 1 UMD were finally determined after reviewing their clinical manifestations ([**Figure 1**](#f1){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}). There were 11 different single-exon deletions in *DMD* gene identified in 15 patients involving exons 2, 13, 44, 45, 50, 51, 52, 53, 55, 61, and 62, respectively, while 36 cases were found to have multiple exon deletions. The largest deletion covering the whole exons from 1 to 79 in *DMD* was found in a 2-month-old male DMD patient (P1) with a higher CK level of 14,982 U/L ([**Table 1**](#T1){ref-type="table"}). The hotspot region was demonstrated between exons 45 and 55 in which 70.6% large deletions were found most frequently, followed by deletions in exons 3--34 (24.4%) ([**Figure 2**](#f2){ref-type="fig"}); three out of four duplications in *DMD* were detected in the proximal hotspot regions between exons 3 and 25 ([**Table 1**](#T1){ref-type="table"}). However, 19 cases failed to detect large deletions or duplications in *DMD* by MLPA.

![The distribution of gross deletions identified in *DMD* gene by MLPA. The frequency of large deletions for each exon of *DMD* gene was shown. The abscissa showed exon number of *DMD* gene from exons 1 to 79; the ordinate demonstrated the frequency of large deletions for each exon. A region with a highest frequency of deletions was found in exons 45--55.](fphar-10-00814-g002){#f2}

Detection of Small Mutations Using NGS {#s3_3}
--------------------------------------

NGS were then utilized to detect small mutations associated with MD in the 19 MLPA-negative patients as well as the two female patients showing MLPA-positive (P5 and P30; see [**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"} for details). Sanger sequencing was used to validate the potentially pathogenic small mutations in the patients and carriers. Overall, 11 point mutations in *DMD* were found in 11 different probands, respectively, which were 3 *de novo* and 8 maternally inherited, including 6 (9.7%) nonsense mutations, 2 (3.2%) small deletions, 2 splice-site mutations (3.2%), and 2 small insertions (1.6%) ([**Figure 1**](#f1){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"}). The point mutations of c.2436C \> T, c.7264dupG, c.1231A \> T, c.5167G \> T, 10187delC, c.7660+1C \> G, and c.7792C \> T in the patients of P52, P53, P54, P57, P58, P59, and P60 were novel, unreported previously. No small mutations were found in the two MLPA-positive female patients. Meanwhile, the known pathogenic mutation c.2049_2050delAG and novel mutation c.1672C \> T in *LAMA2* were detected in two patients of P63 and P64, respectively ([**Figure 1**](#f1){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"}). All the *de novo* mutations were finally predicted to be pathogenic after analysis according to ACMG guideline ([**Table 2**](#T2){ref-type="table"}).

###### 

Summary of putative pathogenic mutations in *DMD*/*LAMA2* gene analyzed by NGS and validated by Sanger sequencing.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient\        Gene/exon        DNA change         Effect               Mutation type   dbSNP/1000G/EVS/ExAC   Status           Inheritance   Pathogenicity prediction score   Pathogenic evaluation according to ACMG   
  ID                                                                                                                                                                                                                        
  --------------- ---------------- ------------------ -------------------- --------------- ---------------------- ---------------- ------------- -------------------------------- ----------------------------------------- ------------
  P52             *DMD/*20         c.2436C \> T       p.Trp812Ter          Nonsense        0/0/0/0                Novel            De novo       1                                                                          Pathogenic

  P53             *DMD/*50         c.7264dupG         p.Ala2422GlyfsTer5   Frameshift      0/0/0/0                Novel            Maternal      1                                                                          Pathogenic

  P54             *DMD/*11         c.1231A \> T       p.Lys411Ter          Nonsense        0/0/0/0                Novel            Maternal      1                                                                          Pathogenic

  P55             *DMD/*7          c.580C \> T        p.Gln194Ter          Nonsense        0/0/0/0                [@B12]           Maternal      1                                                                          Pathogenic

  P56             *DMD/*15         c.1812+1C \> T     --                   Splicing        0/0/0/0                [@B34]; [@B41]   Maternal      1                                1                                         Pathogenic

  P57             *DMD/*37         c.5167G \> T       p.Glu1723Ter         Nonsense        0/0/0/0                Novel            De novo       1                                                                          Pathogenic

  P58             *DMD/*70         10187delC          p.Pro3396GlnfsTer6   Frameshift      0/0/0/0                Novel            Maternal      1                                                                          Pathogenic

  P59             *DMD/*52         c.7660+1C \> G     --                   Splicing        0/0/0/0                Novel            Maternal      1                                1                                         Pathogenic

  P60             *DMD/*53         c.7792C \> T       p.Gln2598Ter         Nonsense        0/0/0/0                Novel            De novo       1                                                                          Pathogenic

  P61             *DMD/*20         c.2571delC         p.Pro857ProfsTer14   Frameshift      0/0/0/0                [@B22]           Maternal      1                                                                          Pathogenic

  P62             *DMD/*43         c.6283C \> T       p.Arg2095Ter         Nonsense        0/0/0/0                [@B6];           Maternal      1                                                                          Pathogenic

  P63             *LAMA2/*exon14   c.2049_2050delAG   p.Arg683SerfsTer21   Nonsense        0/0/0/0                                 Paternal      1                                                                          Pathogenic

  LAMA2/exon 4    DelEX 4          --                 In-frame             0/0/0/0                                Maternal                                                        Pathogenic                                

  P64             LAMA2/exon 4     DelEX 4            --                   In-frame        0/0/0/0                                 Maternal                                                                                 Pathogenic

  LAMA2/exon 12   c.1672C \> T     p.Gln558Ter        Nonsense             0/0/0/0         Novel                  Paternal         1                                              Pathogenic                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All the variants shown in [**Table 2**](#T2){ref-type="table"} are described using the NM_004006.2 of DMD/NM_000426.3 of LAMA2 transcript references, respectively.

del, deletion; dup, duplication; fs, frameshift; Ter, termination; in-frame, in-frame mutation.

ACMG, American College of Medical Genetics and Genomics.

Confirmation of *LAMA2* Mutations in Two MD Patients {#s3_4}
----------------------------------------------------

To further analyze and confirm the possible deletion in *LAMA2* in both patients of P63 and P64, MLPA was performed for detection of *LAMA2* deletion using SALSA MLPA probe sets P391 (MRC-Holland, Amsterdam, the Netherlands) and confirmed that two patients of P63 and P64 harbored DelEX 4 in *LAMA2*. Thus, both compound heterozygous mutations in *LAMA2* were detected in patients of P63 and P64, individually, with P63 carrying c.2049_2050delAG and DelEX 4, whereas P64 having c.1672C \> T and DelEX 4, inherited from father and mother, respectively ([**Table 2**](#T2){ref-type="table"}). After analyzing and comparing the results with the databases, c.1672C \> T (p.Arg2095Ter) was determined as a novel unreported mutation. The clinical symptoms of the two patients showed that they got apparent muscle weakness since the first 6 months of life, hypotonia, poor suck and cry, and delayed motor development, while their parents had normal phenotype. Moreover, clinical laboratory tests showed significantly increased serum CK levels ([**Table 1**](#T1){ref-type="table"}) and typical pattern of myopathy on EMG. So, the two patients were finally diagnosed as Merosin-deficient congenital MD type 1A (MDC1A).

Data Summary {#s3_5}
------------

A total of 70 cases were included in this study, of which 62 were *DMD* gene mutations-positive, and 2 were *LAMA2* mutations-positive detected by MLPA plus NGS. Large deletions and duplications in *DMD* gene were detected in 51 patients by MLPA, of which deletions were found in 47 cases, and duplications were in 4 cases. The remaining 19 cases who were MLPA-negative undergone NGS, and 11 small mutations were identified in 15 male cases. All genetic mutations in *DMD* were shown in [**Table 2**](#T2){ref-type="table"}. The overall positive mutation rate was 91.4% (64/70), encompassing 47 (75.8%) large deletions, 4 (6.5%) large duplications, 6 (9.7%) nonsense mutations, 2 (3.2%) small deletions, 2 (3.2%) splice-site mutations, and 1 (1.6%) small insertion ([**Figure 3**](#f3){ref-type="fig"}).

![The mutation spectrum of *DMD* gene in the cohort. The mutation spectrum of *DMD* gene in the cohort was shown, including 75.8% large deletions, 6.5% large duplications, 9.7% nonsense mutations, 3.2% small deletions, 3.2% splice-site mutations, and 1.6% small insertion.](fphar-10-00814-g003){#f3}

Final diagnosis was made based on the phenotypes and genotypes in the 70 patients. Of them, 34 DMD, 4 BMD, and 2 MDC1A were made. Additional 24 cases couldn't be differentiated between BMD and DMD due to very young age at present and were diagnosed as BMD/DMD. More research in the future need to be done in the remaining six undiagnosed patients ([**Table 3**](#T3){ref-type="table"}).

###### 

Final diagnosis of all 70 patients after detection with MLPA and NGS.

  Final diagnosis            Genotype                               
  -------------------------- ------------ ------------------------- -----------
  DMD                        P34, 48.6%   *DMD*: large deletion     24, 34.3%
  *DMD*: large duplication   4, 5.7%                                
  *DMD*: small mutation      6, 8.6%                                
  BMD                        P4, 5.7%     *DMD*: large deletion     3, 4.3%
  *DMD*: small mutation      1, 1.4%                                
  BMD/DMD\*                  P24, 34.3%   *DMD*: large deletion     20, 28.6%
  *DMD*: small mutation      4, 5.7%                                
  MDC1A                      P2, 2.9%     *LAMA2*: large deletion   2, 2.9%
  *LAMA2*: small mutation    2, 2.9%                                
  Undiagnosed^¶^             P6, 8.6%     No mutation found         6, 8.6%

\*Could not differentiate from each other at present due to very young age of the patients.

^¶^Needs to do more research.

Discussion {#s4}
==========

MDs are a clinically, genetically, and biochemically heterogeneous group of degenerative skeletal muscle disorders. As one of children's rare diseases, diagnosis of MDs still faces many challenges in China ([@B10]; [@B30]). DMD/BMD are the most common types of MD in childhood and caused by the loss of dystrophin function completely or partially ([@B46]; [@B48]). Muscle biopsy, an invasive technique, showing a specific absence of dystrophin protein in DMD patients while partially functional dystrophin protein in BMD, became the golden standard test in diagnosing MD after the 1960s ([@B42]; [@B35]). With the development and availability of genetic techniques, the muscle biopsy has been gradually replaced by gene tests that become the new golden standard as stated in the latest guideline ([@B3]). MLPA has been used to detect large deletion/duplication (≥1 exon) of *DMD* in roughly 70% of cases, and NGS is applied to detect the remaining 25% to 30% small mutations (\<1 exon), such as point mutations and small deletions or insertions, which indicated that MLPA is a simple, rapid, and reliable technique for detection of deletion/duplication in *DMD* gene ([@B48]; [@B46]; [@B39]). Moreover, MLPA has been suggested to use as a first-line screening test for detection of DNA rearrangements in *DMD* in clinically suspected DMD/BMD patients ([@B28]).

In this study, MLPA was firstly applied to detect deletions and duplications in *DMD* in 70 patients with suspected MD, and 38 DNA rearrangements in *DMD* gene were detected in 51 (72.9%) patients (comprised 31 suspected DMD/BMD and 20 UMD). Out of the mutations, 47 large deletions (47/70, 67.14%) and 4 large duplications (4/70, 5.71%) were found, indicating a higher proportion of *DMD* deletion in comparison with *DMD* duplication, which is similar as the most previous studies ([@B7]; [@B29]; [@B5]; [@B9]; [@B33]; [@B39]) but different from some reports that demonstrated about 40% deletion and about 25% duplication ([@B18]; [@B43]; [@B21]). So, further investigation of the differences in different populations from various locations still needs to be done.

Despite distribution of deletions and duplications occurring in almost every exon in *DMD* gene, two deletion hot spot regions with a non-random style have been repeatedly reported at the 5'-end and the central region around exons 44 to 55 ([@B29]; [@B1]; [@B39]; [@B28]). In our cohort, we could detect the deletion hot spot in the central region of exons 45 to 55, with a distribution rate in this region of approximately 70.6%, which is in accordance with previous studies ([@B7]; [@B18]; [@B21]; [@B5]; [@B33]). Out of four duplications detected in this study, three showed in the proximal hot spot region from exons 3 to 25 similar as the previous report ([@B33]).

With the great advantage of cost-effectiveness and accuracy, NGS has made the detection of small mutations in *DMD* revolutionized ([@B49]; [@B19]). To minimize the cost of NGS for detection of mutations, we utilized NGS in the remaining 19 MLPA-negative (13 DMD/BMD and 6 UMD) patients and the two female patients of MLPA-positive. In total, 13 small mutations in 13 (7 DMD/BMD, 6 UMD) patients were found, including 11 *DMD* mutations (three *de novo* and eight maternal inheritances) and 2 *LAMA2* mutations. Among 11 point mutations of *DMD* gene, 6 were nonsense mutations (54.55%), which were the most common point mutations in this study, similar to the report ([@B33]), and then followed by splice-site mutations (18.2%), small deletions (18.2%), and small insertions (9.1%); however, no missense mutations were detected in this cohort, which might be due to the small sample size. The distribution of mutations types (six nonsense, three frameshift, and two splicing) in this study was consistent with some studies using different methods ([@B12]; [@B40]; [@B23]). As expected, G:C to A:T transitions were the most prevalent stop mutation class; our results showed that the transversions of GC to AT accounted for 63.63% (7/11). After mutation verification of the probands' mothers, eight novel (seven in *DMD* and one in *LAMA2*) mutations were identified. All these novel mutations were predicted to generate a premature stop codon in the coding sequence of *DMD* causing premature termination of the protein product lacking key domains of dystrophin protein, and produce a non-functional dystrophin protein thereby leading to DMD. In this way, we got much higher detection rate of 91.4% than muscle biopsies with more precise and sensitive diagnosis of MD.

Two unrelated female patients clinically diagnosed as DMD-like MD ([**Table 1**](#T1){ref-type="table"}), whose parents showed normal phenotypes, were detected to carry a heterozygous deletion of exon 50 and exons 8--12 in *DMD* by MLPA, inherited maternally, but no disease-causing small mutations were found by the NGS. As we know, most heterozygous *DMD* mutations' female carriers were asymptomatic, however, although of which 2.5--7.8% were symptomatic with symptoms ranging from mild muscle weakness to a rapidly progressive DMD-like MD ([@B27]; [@B32]; [@B41]). Fujii et al. (2009) summarized the mechanism for female DMD and BMD as the following five cases: uniparental disomy of the entire X chromosome with mutations, skewed X inactivation either balanced X-autosome translocation patients or in the female carriers with *dystrophin* mutation, Turner syndrome with a *dystrophin* mutation on the remaining X chromosome, co-occurrence of mutations in both *dystrophin* and androgen receptor genes, and double *dystrophin* mutations on both X chromosomes. In regard of the two female cases in this study, the most probable mechanism is skewed X inactivation in the female *dystrophin* mutation carriers. The further X chromosome inactivation analyses of the two patients are required to confirm the inference.

In this cohort, 28 UMD patients presented only persistent hyperCKemia (CK from 2,391 to 35,340 U/L) and typical myopathy performance on EMG but without typical clinical features due to very young age (average age at 0.64 ± 0.34 years). After detecting mutation using the MLPA plus NGS, 24 mutations in *DMD* were found, including 20 large deletions and 3 nonsense and 1 splice-site mutations. Additionally, two small mutations in *LAMA2* were detected. *Laminin-α2* (*LAMA2*) is the causative gene to MDC1A (merosin-deficient congenital MD type 1A), which is a type of CMD, an autosomal recessive disorder. So far, more than 493 mutations in *LAMA2* gene have been listed in the locus specific database (LSDB) (April, 2018), in which a limited number of large deletions/duplications have been reported. In this study, deletions of exon 4 in *LAMA2* in the two patients with MDC1A were detected, respectively, which have been reported in five other Chinese patients by [@B47], but have not been found in other countries. So, we inferred that it might be a particular mutation type in Chinese population. In addition, the mutation c.2049_2050delAG in *LAMA2* in patient P63 was a known pathogenic mutation ([@B15]), while c.1672C \> T (p.Q558X) in *LAMA2* in patient P64 was a *de novo* nonsense mutation, unreported in population databases (ExAC, dbSNP, and 1,000 genomes), leading to a truncated and nonfunctional laminin-α2 protein, which was also predicted to be pathogenic by using MutationTaster. Moreover, many pathogenic truncating mutations downstream of this mutation site have been reported in the LSDB for the *LAMA2* gene (<http://www.lovd.nl/LAMA2>). Thus, we inferred that the mutation c.1672C \> T (p.Q558X) in *LAMA2* was probably pathogenic.

To the best of our knowledge, this is the first report using the molecular genetics techniques to identify genes' mutations in young patients with MD before their clinical features appeared. And it is critical to perform molecular genetics detection for the UMD patients with indicators like persistent hyperCKemia and typical myopathy performance on EMG but without definite clinical manifestations at a relatively young age. The genotype-first approach can provide a definitive diagnosis mainly based on molecular evidence ([@B36]). This study of using MLPA plus NGS provides a comprehensive and effective genetic approach for precise and early diagnosis of MD, with the diagnostic yield of 91.4% (64/70).

Conclusions {#s5}
===========

In this study, we identified 51 large deletions/duplications, 11 small mutations in *DMD* gene, and 2 mutations in *LAMA2* gene by MLPA plus NGS. We finally diagnosed 34 DMD, 4 BMD, 24 BMD/DMD, and 2 MDC1A in the cohort. Our data indicated that the MLPA plus NGS can be a comprehensive and effective tool for precision diagnosis of MD and is particularly necessary for the patients with only two clinical indicators (persistent hyperCKemia and typical myopathy performance on electromyogram) but no definite clinical manifestations at a relatively young age, which would benefit the very young patients for early diagnosis and treatment as well. Moreover, the method is suitable for early precise diagnosis of children with unclear clinical subtypes of MD.
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